arrow
I

Inderjit Mehmi

the angeles clinic and research institute
H指数:23
被引数:2,160

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

黑色素瘤新辅助治疗的五年生存率:国际黑色素瘤新辅助治疗协作组(INMC)更新的汇总分析

2026-10-010
OAAI
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial

LOAd703诱导的肿瘤微环境基因工程与atezolizumab联合治疗转移性恶性黑色素瘤:一项I/II期临床试验

2026-02-160
OAAI
Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses
2025-12-310
PRE
A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors

一项关于modakafusp alfa单药及联合pembrolizumab治疗晚期或转移性实体瘤的Ib/II期研究

2025-12-090
OAAI
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study

妊娠期晚期黑色素瘤:一项回顾性、多中心、基于注册研究的建议

2025-10-070
OAAI
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients

联合局部疗法可延长tebentafusp在转移性眼葡萄膜黑色素瘤患者中的临床获益

2025-10-010
OAAI
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade–resistant melanoma: Final analysis from a phase 1b study

肿瘤内注射vidutolimod作为单药治疗或与pembrolizumab联用,用于程序性细胞死亡1阻滞剂耐药性黑色素瘤患者的最终分析:一项1b期研究的结果

Cancer
IF5.1
2025-08-030
OAAI
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial

新辅助抗PD-1单药或联合抗TIGIT或溶瘤病毒在可切除的III B-D期黑色素瘤中的应用:一项I/II期临床试验

2025-01-072
OA
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
2025-01-010
OAAI
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

切除的III/IV期肢端或粘膜黑色素瘤患者的结果,以anti-PD-1为基础的辅助治疗

2024-03-016
PRE
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma
2023-10-010
OAAI
Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
2023-04-140
PRE
KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) plus vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
2023-04-148
PRE
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
2022-09-0129
OA
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
2022-07-0627
OAAI